Assignee
ARRAY BIOPHARMA INC
US·217 granted patents·73 pending applications·2,267 citations·filing 1998–2025
Top patents by PatentIndex Score
290 records- 0199US9676783B2Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compoundsARRAY BIOPHARMA INC·Filed 2015·Granted Jun 13, 2017·23 cites·83 claims
- 0299US9127013B2Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compoundsARRAY BIOPHARMA INC·Filed 2015·Granted Sep 8, 2015·47 cites·30 claims
- 0399US8865698B2Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compoundsARRAY BIOPHARMA INC·Filed 2013·Granted Oct 21, 2014·45 cites·33 claims
- 0498US10174028B2Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2018·Granted Jan 8, 2019·14 cites·29 claims
- 0598US10174027B2Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2017·Granted Jan 8, 2019·17 cites·30 claims
- 0698US10138243B2Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2018·Granted Nov 27, 2018·14 cites·29 claims
- 0798US10112942B2Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2017·Granted Oct 30, 2018·29 cites·30 claims
- 0898US9493476B2Macrocyclic compounds as trk kinase inhibitorsARRAY BIOPHARMA INC·Filed 2014·Granted Nov 15, 2016·46 cites·14 claims
- 0998US9447104B2Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compoundsARRAY BIOPHARMA INC·Filed 2014·Granted Sep 20, 2016·21 cites·92 claims
- 1097US10953005B1Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2020·Granted Mar 23, 2021·4 cites·16 claims
- 1197US10137124B2Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2018·Granted Nov 27, 2018·12 cites·29 claims
- 1297US10047097B2Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compoundsARRAY BIOPHARMA INC·Filed 2018·Granted Aug 14, 2018·9 cites·22 claims
- 1397US10023570B2Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2016·Granted Jul 17, 2018·14 cites·103 claims
- 1497US10005783B2Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compoundsARRAY BIOPHARMA INC·Filed 2017·Granted Jun 26, 2018·10 cites·140 claims
- 1597US9902741B2Macrocyclic compounds as TRK kinase inhibitorsARRAY BIOPHARMA INC·Filed 2017·Granted Feb 27, 2018·22 cites·15 claims
- 1697US9840519B2Macrocyclic compounds as TRK kinase inhibitorsARRAY BIOPHARMA INC·Filed 2016·Granted Dec 12, 2017·21 cites·5 claims
- 1797US9750744B2Macrocyclic compounds as Trk kinase inhibitorsARRAY BIOPHARMA INC·Filed 2017·Granted Sep 5, 2017·21 cites·29 claims
- 1897US9718822B2Macrocyclic compounds as Trk kinase inhibitorsARRAY BIOPHARMA INC·Filed 2017·Granted Aug 1, 2017·22 cites·15 claims
- 1996US10208024B22-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinasesARRAY BIOPHARMA INC·Filed 2016·Granted Feb 19, 2019·32 cites·27 claims
- 2096US10172851B2Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2018·Granted Jan 8, 2019·8 cites·29 claims
- 2196US9796724B2Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitorsARRAY BIOPHARMA INC·Filed 2017·Granted Oct 24, 2017·16 cites·30 claims
- 2296US9782415B2Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitorsARRAY BIOPHARMA INC·Filed 2017·Granted Oct 10, 2017·19 cites·30 claims
- 2396US7799782B2P38 inhibitors and methods of use thereofARRAY BIOPHARMA INC·Filed 2009·Granted Sep 21, 2010·600 cites·23 claims
- 2496US7732616B2Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereofARRAY BIOPHARMA INC·Filed 2006·Granted Jun 8, 2010·35 cites·1 claims
- 2596US7517994B2Heterocyclic inhibitors of MEK and methods of use thereofARRAY BIOPHARMA INC·Filed 2005·Granted Apr 14, 2009·36 cites·1 claims
- 2696US7449486B2Mitotic kinesin inhibitors and methods of use thereofARRAY BIOPHARMA INC·Filed 2005·Granted Nov 11, 2008·37 cites·34 claims
- 2796US7425637B2N3 alkylated benzimidazole derivatives as MEK inhibitorsARRAY BIOPHARMA INC·Filed 2005·Granted Sep 16, 2008·27 cites·1 claims
- 2895US9796723B2Method of treatment using substituted imidazo[1,2b]pyridazine compoundsARRAY BIOPHARMA INC·Filed 2017·Granted Oct 24, 2017·15 cites·30 claims
- 2995US9795611B2Method of treatment using substituted imidazo[1,2b]pyridazine compoundsARRAY BIOPHARMA INC·Filed 2017·Granted Oct 24, 2017·15 cites·30 claims
- 3095US9682979B2Substituted pyrazolo [1,5-A] pyrimidine compounds as TRK kinase inhibitorsARRAY BIOPHARMA INC·Filed 2014·Granted Jun 20, 2017·27 cites·43 claims
- 3195US8003651B2Pyrimidyl cyclopentanes as AKT protein kinase inhibitorsARRAY BIOPHARMA INC·Filed 2007·Granted Aug 23, 2011·35 cites·76 claims
- 3295US7777032B2Quinazoline analogs as receptor tyrosine kinase inhibitorsARRAY BIOPHARMA INC·Filed 2009·Granted Aug 17, 2010·11 cites·2 claims
- 3395US7585975B2Quinazoline analogs as receptor tyrosine kinase inhibitorsARRAY BIOPHARMA INC·Filed 2008·Granted Sep 8, 2009·11 cites·16 claims
- 3494US11414404B2Compounds for the treatment of BRAF-associated diseases and disordersARRAY BIOPHARMA INC·Filed 2020·Granted Aug 16, 2022·5 cites·14 claims
- 3594US10555944B2Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2018·Granted Feb 11, 2020·10 cites·12 claims
- 3694US9782414B2Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfateARRAY BIOPHARMA INC·Filed 2017·Granted Oct 10, 2017·22 cites·30 claims
- 3794US7777050B2N3 alkylated benzimidazole derivatives as MEK inhibitorsARRAY BIOPHARMA INC·Filed 2008·Granted Aug 17, 2010·13 cites·9 claims
- 3894US7169926B1Dipeptidyl peptidase inhibitorsARRAY BIOPHARMA INC·Filed 2004·Granted Jan 30, 2007·68 cites·72 claims
- 3993US10780073B2N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseasesARRAY BIOPHARMA INC·Filed 2018·Granted Sep 22, 2020·7 cites·24 claims
- 4093US10647730B2Macrocyclic compounds as TRK kinase inhibitorsARRAY BIOPHARMA INC·Filed 2018·Granted May 12, 2020·4 cites·15 claims
- 4193US10172861B2Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfateARRAY BIOPHARMA INC·Filed 2018·Granted Jan 8, 2019·15 cites·18 claims
- 4293US10143692B2Polymorphs of ARRY-380, a selective HER2 inhibitor and pharmaceutical compositions containing themARRAY BIOPHARMA INC·Filed 2018·Granted Dec 4, 2018·7 cites·36 claims
- 4393US10011604B2Method of treatment using substituted imidazo[1,2b]pyridazine compoundsARRAY BIOPHARMA INC·Filed 2015·Granted Jul 3, 2018·9 cites·18 claims
- 4493US9889134B2Polymorphs of ARRY-380, a selective HER 2 inhibitor and pharmaceutical compositions containing themARRAY BIOPHARMA INC·Filed 2015·Granted Feb 13, 2018·8 cites·16 claims
- 4593US9168254B2Polymorphs of ARRY-380, a selective HER 2 inhibitor and pharmaceutical compositions containing themARRAY BIOPHARMA INC·Filed 2012·Granted Oct 27, 2015·15 cites·127 claims
- 4693US8697715B2Serine/threonine kinase inhibitorsARRAY BIOPHARMA INC·Filed 2013·Granted Apr 15, 2014·21 cites·25 claims
- 4793US7235537B2N3 alkylated benzimidazole derivatives as MEK inhibitorsARRAY BIOPHARMA INC·Filed 2003·Granted Jun 26, 2007·53 cites·10 claims
- 4892US10584124B2Crystalline formsARRAY BIOPHARMA INC·Filed 2018·Granted Mar 10, 2020·12 cites·9 claims
- 4992US9850230B2Compounds and compositions as protein kinase inhibitorsARRAY BIOPHARMA INC·Filed 2016·Granted Dec 26, 2017·7 cites·9 claims
- 5092US9593100B2Compounds and compositions as protein kinase inhibitorsARRAY BIOPHARMA INC·Filed 2016·Granted Mar 14, 2017·7 cites·25 claims
Showing the top 50 of 290 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →